CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.

ABSTRACT: CD44 is a transmembrane glycoprotein involved in numerous cellular functions, including cell adhesion and extracellular matrix interactions. It is known to be functionally diverse, with alternative splice variants increasingly implicated as a marker for tumor-initiating stem cells associated with poor prognosis. Here, we evaluate CD44 as a potential marker of long-term breast cancer outcomes. Tissue specimens from patients treated on the National Cancer Institute 79-C-0111 randomized trial of breast conservation versus mastectomy between 1979 and 1987 were collected, and immunohistochemistry was performed using the standard isoform of CD44. Specimens were correlated with patient characteristics and outcomes. Survival analysis was performed using the log rank test. Fifty-one patients had ev

SUBMITTER: Dan T 

PROVIDER: S-EPMC7668685 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature